What records are connected here?
- Evidence lanes
- 3
- Source years
- 17
- Drugs@FDA applications
- 8
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2Evidence: Large human trialsHormones · Sexual and reproductive health
Ganirelix is a synthetic decapeptide that blocks the gonadotropin-releasing hormone (GnRH) receptor in the pituitary gland.1 FDA approved Organon’s ganirelix acetate in 1999 to prevent a premature surge of luteinizing hormone (LH) in women undergoing controlled ovarian hyperstimulation for fertility treatment.1,2 Its label describes two well-controlled studies, including a randomized trial in which 463 women received ganirelix with a GnRH agonist as the reference treatment.1
| What it is | A synthetic decapeptide derived from natural GnRH with amino acids changed at six positions, giving it strong GnRH-blocking activity, according to the label.1 |
|---|---|
| FDA status | FDA-approved. Drugs@FDA lists Organon’s ganirelix acetate, NDA 021057, with an original approval date of July 29, 1999. The cited label has no boxed warning.1,2 |
| Human evidence | A double-blind, randomized study in 332 women and an open-label, randomized study in which 463 women received ganirelix, both described in the label.1 |
| Evidence strength | Large randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned |
Ganirelix is a synthetic decapeptide derived from natural gonadotropin-releasing hormone (GnRH), with substitutions at positions 1, 2, 3, 6, 8 and 10 that make it a strong GnRH blocker, according to the label.1
Drugs@FDA lists the original application, ganirelix acetate from Organon (NDA 021057). Other companies also hold approvals for ganirelix.2
The label states that ganirelix competitively blocks GnRH receptors on the pituitary, causing a rapid, reversible suppression of gonadotropin release that is more pronounced for LH than for FSH.1
The label states that effectiveness was established in two adequate and well-controlled studies in women with normal hormone and pelvic ultrasound findings, excluding women with polycystic ovary syndrome or low ovarian reserve.1
In a double-blind, randomized study of 332 women undergoing ovarian hyperstimulation for IVF, LH on the day of the final trigger fell as the amount of ganirelix increased, according to the label.1
In an open-label, randomized study, 463 women received ganirelix and the label reports their hormone levels and pregnancy outcomes alongside a GnRH agonist reference group.1
Evidence-strength label: Large randomized human trials. How this label is assigned
Yes. Drugs@FDA lists Organon’s ganirelix acetate, application NDA 021057, with an original approval date of July 29, 1999.2
The label cited here (DailyMed SPL version 10, published October 12, 2026) states that it is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation.1
The label has no boxed warning. It is contraindicated in known or suspected pregnancy and in people allergic to GnRH or its analogues.1
Its effects in women excluded from the studies, such as those with polycystic ovary syndrome or low ovarian reserve, according to the label.1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Ganirelix: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Ganirelix are a bounded selection, not every registration or paper about Ganirelix. For the years before Ganirelix was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Ganirelix as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Ganirelix in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as ganirelix acetate for use in controlled ovarian hyperstimulation. The label describes two well-controlled studies, including randomized studies of 332 women and of 463 women treated with ganirelix.↗↗
Status sources checked through November 15, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as ganirelix acetate for use in controlled ovarian hyperstimulation. The label describes two well-controlled studies, including randomized studies of 332 women and of 463 women treated with ganirelix.↗↗
The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Clinical trials · source date July 2, 2026
ClinicalTrials.gov record NCT06745466↗Added to PeptideScanner November 15, 2026Clinical trials · added November 15, 2026
ClinicalTrials.gov record NCT06745466↗Source date July 2, 2026Clinical trials · added November 15, 2026
ClinicalTrials.gov record NCT05954962↗Source date March 27, 2026Literature metadata · added November 15, 2026
New local ganirelix sustained release therapy for uterine leiomyoma. Evaluation in a preclinical organ model.↗Source date January 27, 2026PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
22 of 27 selected trial records include at least one phase value; 27 of 27 include a status value in the retained structured contract.
A phase value is unavailable here for 5 selected records; this is not counted as “no phase.”
6 of 6 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT00225433 at 2026-11-15T22:03:26.540Z. Its registry update date was 2015-12-03, and PeptideScanner's reviewed identity mapping was ganirelix.
PeptideScanner retained ClinicalTrials.gov record NCT00461422 at 2026-11-15T22:03:26.540Z. Its registry update date was 2008-06-27, and PeptideScanner's reviewed identity mapping was ganirelix.
PeptideScanner retained ClinicalTrials.gov record NCT00589134 at 2026-11-15T22:03:26.540Z. Its registry update date was 2020-03-30, and PeptideScanner's reviewed identity mapping was ganirelix.
6 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span July 29, 1999 to July 2, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06745466 at 2026-11-15T22:03:26.540Z. Its registry update date was 2026-07-02, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05954962 at 2026-11-15T22:03:26.540Z. Its registry update date was 2026-03-27, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Literature metadata
PubMed lists PMID 36279721 in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie as Journal Article, with publication-date metadata of 2022-10-21 (day precision). PeptideScanner associated the retained record with the identity slug ganirelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03142893 at 2026-11-15T22:03:26.540Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04037605 at 2026-11-15T22:03:26.540Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 219454 with status AP dated 2025-06-27, and names ganirelix acetate among the application record's active ingredients.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05751252 at 2026-11-15T22:03:26.540Z. Its registry update date was 2025-04-27, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 218855 with status AP dated 2025-04-23, and names ganirelix acetate among the application record's active ingredients.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06091436 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-12-03, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00703014 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-09-19, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00702273 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-09-05, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00988260 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-08-15, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026